[ad_1]
Chardan Capital restated a “buy” rating and set a $13.00 price target on shares of Immuneering in a research note on Thursday.
[ad_2]
Source link
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital
Related Posts
DoorDash, McDonald’s, Shopify Stocks Show Mixed Consumer Mood
[ad_1] Earnings season is not only an opportunity for investors to evaluate the success (or lack thereof) of individual companies…
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Brokerages
[ad_1] Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus recommendation of “Hold” from the eighteen…
JTC (LON:JTC) Stock Price Up 12.7% – Here's Why
[ad_1] JTC (LON:JTC) Stock Price Up 12.7% – Still a Buy? [ad_2] Source link